TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20135139
Drug: Bevacizumab administered
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab administered 7 days before vitrectomy
Study: 23636185
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (1 mL methylprednisolone [40 mg] and 1 mL 2% lignocaine)
Study: 16271721
Drug: Intramuscular oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular oxytocin
Study: 30141230
Drug: Proton therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton therapy with uniform scanning or pencil beam scanning, prescribed doses of 50.4‐66.4 Gy(RBE) scaled to 50.4 Gy(RBE) for analysis.
Study: 2031520
Drug: Ofloxacin, 400
Normalized name: Ofloxacin, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin, 400 mg twice daily for 10 days
Study: 10993998
Drug: Low-dose olanzapine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose olanzapine (2.5 to 7.5 mg/day)
Study: 2864944
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus dose of vecuronium (10-50 micrograms kg-1)
Study: 16616147
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 1800 mg/day
Study: 20234330
Drug: 2-week antibiotic
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week antibiotic treatment regimen
Study: 20234330
Drug: 3-week antibiotic
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week antibiotic treatment regimen
Study: 31132094
Drug: Oral contraception
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraception during treatment
Study: 1560699
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (ACV)
Study: 10419245
Drug: Ibuprofen to
Normalized name: Ibuprofen to Go
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen to prevent recurrent febrile seizures
Study: 27281084
Drug: Perineural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perineural dexamethasone 5 mg
Study: 31571571
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of autologous, microfragmented adipose tissue
Study: 9422205
Drug: Monocytic HLA-DR
Normalized name: Dr. Numb
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monocytic HLA-DR expression measurement in dermatological patients receiving high dose systemic steroids
Study: 19192477
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol alone
Study: 15179345
Drug: Conventional anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anesthesia (G‐CA)
Study: 23642943
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (2 g per day, single dosage of two 1 g pearls)
Study: 2656902
Drug: Felodipine plain
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine plain tablet (10 mg)
Study: 28941657
Drug: Complex decongestive
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex decongestive therapy (CDT)
Study: 17410120
Drug: Mesoridazine 50
Normalized name: mesoridazine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesoridazine 50 mg
Study: 28967272
Drug: Methotrexate monotherapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate monotherapy with glucocorticoid bridging
Study: 10506877
Drug: Cefuroxime axetil,
Normalized name: Cefuroxime Axetil, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime axetil, 500 mg/d
Study: 1951871
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin subcutaneously
Study: 23807155
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg TAF
Study: 6345308
Drug: Galphimia glauca
Normalized name: Galphimia Glauca
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galphimia glauca D4 therapy
Study: 16787141
Drug: Anti-VEGF drugs
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF drugs
Study: 26542030
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment
Study: 1595785
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin plus low-dose aspirin
Study: 17996241
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg niacin for 6 weeks
Study: 9578254
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate 1 ml (10 mg) injected into the superior compartment of the temporomandibular joint
Study: 30376089
Drug: Oral Polio
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Polio Vaccine (OPV) shedding
Study: 26730967
Drug: Brushing and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brushing and immersion in water with a cleansing tablet
Study: 18599016
Drug: Oral 13-cis-retinoic
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 13-cis-retinoic acid (RA) 10 mg twice daily for eight weeks
Study: 15611537
Drug: Nurse delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse delivered analgesia with morphine via conventional route
Study: 28385654
Drug: Routine preoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine preoperative preparation for one week (CG)
Study: 7792376
Drug: Guided imagery
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided imagery preparation
Study: 30663606
Drug: CVT-301 84
Normalized name: CVT-6883
DrugBank: CVT-6883 (DB05936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVT-301 84 mg
Study: 17243057
Drug: pegylated IFN-alpha-2b
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pegylated IFN-alpha-2b (1.0 micro g/kg)
Study: 10319771
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution infusion (30 ml x kg(‐1) x h(‐1))
Study: 1862584
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tenoxicam daily for ten days
Study: 30463820
Drug: Atomization inhalation
Normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomization inhalation of terbutaline followed by nebulized inhalation of budesonide
Study: 22209361
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg
Study: 20826076
Drug: Juvenile drug
Normalized name: CUNNINGHAM CLAMP,JUVENILE,BARD #004052
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juvenile drug court (JDC) intervention
Study: 16129614
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tube thoracostomy and streptokinase instillation (group B)
Study: 7641922
Drug: Intrauterine insemination
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine insemination (IUI) with clomiphene citrate (CC)
Study: 11135211
Drug: Cyclophosphamide 100
Normalized name: cyclophosphamide 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 100 mg/m(2) orally on Days 1-14, methotrexate 40 mg/m(2) and 5-fluorouracil 500 mg/m(2) intravenously on Days 1 and 8 every 4 weeks (CMF)
Study: 16426468
Drug: Gabapentin 400
Normalized name: gabapentin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 400 mg 6 hourly
Study: 9781802
Drug: Oral IFN-alpha
Normalized name: Alpha-caine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral IFN-alpha (200 IU daily sublingual dose)
Study: 27155753
Drug: SFC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC group (25/50 μg b.i.d.)
Study: 29960692
Drug: Pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill placebo
Study: 8986681
Drug: 2.5 mg/d
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/d tibolone (n = 15)
Study: 11379362
Drug: Eradication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication treatment (pantoprazole 40 mg once daily, amoxycillin 100 mg b.i.d., clarithromycine 500 mg b.i.d.)
Study: 30522667
Drug: RESOLUTE Integrity
Normalized name: Motegrity
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: RESOLUTE Integrity drug-eluting stent (DES)
Study: 11751775
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of ceftazidime
Study: 8569363
Drug: Horse-chestnut seed
Normalized name: horse chestnut seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horse-chestnut seed extract (HCSE, 50 mg aescin, twice daily)
Study: 1722443
Drug: Islet amyloid
Normalized name: Islet amyloid polypeptide
DrugBank: Amlintide (DB16614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islet amyloid polypeptide infusion (150 pmol min‐1 kg‐1)
Study: 30823945
Drug: Liraglutide combined
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide combined with insulin
Study: 25302456
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL 1% lignocaine PPNB and 100 mg diclofenac suppository
Study: 17244282
Drug: Mitomycin-C (MMC)
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin-C (MMC) 40 mg
Study: 29289702
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of financial incentives for dietary self-monitoring and interim weight loss
Study: 17244282
Drug: Bacillus Calmette-Guérin
Normalized name: Bacillus Calmette-Guérin (BCG) vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guérin (BCG) 120 mg
Study: 30682452
Drug: Azithromycin (AZM)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (AZM) treatment
Study: 7517829
Drug: Intensive drug
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive drug treatment (in men)
Study: 31348349
Drug: Hand therapy
Normalized name: Octinoxate 3.00 mL in 75 mL / Avobenzone 1.5 mL in 75 mL TOPICAL CREAM [Botanics Daily Hand Therapy Sunscreen SPF 10]
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand therapy (shorter duration)
Study: 25702958
Drug: Usual protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual protein intake (UP, <1.2 g of protein/kg body weight/d)
Study: 20439572
Drug: Herpes zoster
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herpes zoster vaccine
Study: 9578931
Drug: Combined ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined ipratropium bromide (0.06% two sprays per nostril) and oxymetazoline (0.05% two sprays per nostril)
Study: 24090124
Drug: Teflon infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Teflon infusion set
Study: 17684125
Drug: Regular ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Regular ibuprofen users homozygous for the variant allele at either M9V or D175G
Study: 19842721
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (2000-U bolus + 500 U/h)
Study: 22879314
Drug: basic fibroblast
Normalized name: Basic Fibroblast Growth Factor
DrugBank: Basic Fibroblast Growth Factor (DB14131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: basic fibroblast growth factor (bFGF) treatment
Study: 25424454
Drug: 3 h
Normalized name: Type 3 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 h 100 g OGTT using the Carpenter‐Coustan criteria
Study: 25424454
Drug: 2 h
Normalized name: Type 2 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 h 75 g OGTT or whichever test is recommended by their doctor
Study: 16022966
Drug: Metyrapone 750
Normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metyrapone 750 mg x 2
Study: 25125441
Drug: Sham electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham electrical stimulation combined with repetitive task practice therapy
Study: 26727697
Drug: Tonsillectomy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonsillectomy combined with drug therapy (Group A)
Study: 19834016
Drug: Loose control
Normalized name: Goose
DrugBank: Goose (DB10874)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loose control (target 70 to 200 mg/dL)
Study: 105622
Drug: Type B
Normalized name: HLA type B IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type B vitamin combination (5 mg/day thiamin HCl and 3 mg/day pyridoxine HCl)
Study: 105622
Drug: Type C
Normalized name: HLA type C IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type C vitamin combination (5 mg/day thiamin HCl and 3 mg/day pyridoxine HCl)
Study: 105622
Drug: Type A
Normalized name: HLA type A IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type A vitamin combination (55 mg/day thiamin HCl and 102 mg/day pyridoxine HCl)
Study: 15610940
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) isradipine 15 mg
Study: 20051377
Drug: Sulindac 150
Normalized name: sulindac 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac 150 mg twice daily for 6 weeks
Study: 12067330
Drug: IgG anti-GM1
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IgG anti-GM1 antibodies in normal controls (detection via ELISA, initial dilution 1:200, positive at absorbance > 0.1)
Study: 2303582
Drug: ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen 800 mg aqueous suspension
Study: 2303582
Drug: ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen 800 mg orange juice suspension
Study: 8122728
Drug: Weekly donation
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly donation intervals (group II)
Study: 10806602
Drug: Sibrafiban with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibrafiban with heparin
Study: 6689389
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 20 mg
Study: 30836981
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of renin-angiotensin system inhibitors (RASi)
Study: 4140268
Drug: Atropine injection
Normalized name: atropine Injection
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine injection
Study: 30501824
Drug: Dexamethasone administration
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone administration to women before elective cesarean section (group 1)
Study: 15846191
Drug: Brief folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief folic acid counseling, a reminder phone call, and 30 folic acid tablets (n = 162 women)
Study: 30317548
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (20,000 IU weekly)
Study: 12092646
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (75 mg intramuscularly)
Study: 15370723
Drug: Etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 mg
Study: 8769362
Drug: Combined GH
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined GH and T3 administration
Study: 9125680
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (1, 2, and 4 microg/100 ml forearm tissue/min)
Study: 820813
Drug: Antibiotic usage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic usage
Study: 25278342
Drug: Self-control strength
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-control strength training (maximal endurance contractions of spring handgrip trainers, twice daily)
Study: 9006561
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy after BCS in Ontario
Study: 12472985
Drug: Haloperidol 20
Normalized name: haloperidol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 20 mg/day plus Diazoxide 200 mg/day
Study: 12472985
Drug: Haloperidol 20
Normalized name: haloperidol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 20 mg/day plus Placebo
Study: 22368281
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg
Study: 18997143
Drug: White patients
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White patients not filling prescription medications
Study: 24660604
Drug: Reduning injection
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduning injection (Group B)
Study: 11450868
Drug: Amoxicillin 3
Normalized name: amoxicillin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 3 g and clavulanic acid 750 mg, 1 dose daily for 2 days
Study: 29365351
Drug: icosapent ethyl
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: icosapent ethyl 4 g/d
Study: 9468240
Drug: 6 MU
Normalized name: Pancrelipase 16 mu
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 MU of interferon daily for 4 weeks followed by 6 MU three times weekly for 18 weeks (total dose, 660 MU)
Study: 2012351
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of therapy with trimethoprim-sulfamethoxazole (160-800 mg twice daily)
Study: 18979160
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU daily cholecalciferol
Study: 12773957
Drug: Oral ethinyl
Normalized name: ethinyl estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ethinyl oestradiol
Study: 7808029
Drug: ATRA and
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA and intensive chemotherapy
Study: 17021318
Drug: Sham injections
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injections
Study: 25925891
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sipuleucel-T with AA + P
Study: 14762867
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) at a dose of 10mg/kg/h
Study: 14762867
Drug: Aprotinin (AP)
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin (AP) with a loading dose of 2 x 10(6) KIU followed by an infusion of 500,000 KIU/h
Study: 10094218
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (500 microg twice daily) via Diskus
Study: 19231633
Drug: A-002 (1-H-indole-3-glyoxamide)
Normalized name: heparinoids 0.002 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-002 (1-H-indole-3-glyoxamide) 500 mg twice daily
Study: 9119355
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (radiotherapy followed by melphalan and prednisone every 6 weeks for 3 years)
Study: 27037462
Drug: Short-interval misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-interval misoprostol (2 placebo tablets at 12 hours and 2 tablets of 400 μg at 3 hours before procedure)
Study: 22609108
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m(2) and nedaplatin 80 mg/m(2) intravenously on day 1 every 28 days